What is BCDA's 12-month stock price target?

BioCardia Inc. (BCDA) carries a 12-month consensus base price target of $0.81 (-10% from $0.90), with a bull-case target of $1.89 and a bear-case floor of $0.63.

Stock Ratings / Health Care / BCDA / forecast

ATYR (46) ABOS (33) DYAI (31) PASG (34) ⌘ Pro Terminal →

BioCardia Inc. (BCDA) 12-Month Stock Forecast & Price Target Cone

Q: Is BCDA stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates BCDA D- (Sell — SELL) with an RQD Confidence score of 37/100.

$0.90 +4.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.91

BioCardia Inc. (BCDA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $13.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BCDA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BCDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BioCardia Inc. (NASDAQ: BCDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.90 (+4.75% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BCDA ranks #549 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BCDA compare to ATYR and ABOS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BCDA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ATYR (aTyr Pharma Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and ABOS (Acumen Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M). Among the 5-stock peer group, BCDA leads on earnings multiple (N/A) while BCDA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BCDA?

▼

Per BCDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000925741), BioCardia Inc. generated $23.2M in revenue (+3.5% YoY), -$8.2M in net income, and -$7.4M in free cash flow against $3.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.91 (+0.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCDA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY BCDA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 14% of 52W Range • RSI-14 at 40 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.99+5.1% Next Q

Q2 (-2Q)

Grade D$1.04-11.5% Next Q

Q3 (-1Q)

Grade D$0.92-2.2% Next Q

Current

Grade D-$0.90-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BCDA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BCDA currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.04) and Max Pain ($0.95) forces dealer call-delta covering toward $1.89.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BCDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your BCDA Position Size: $10,000

Shares at $0.90: 11111.1 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.63

$7,000

$-3,000 (-30.0%)

12M Consensus BaseTarget $0.81

$9,000

$-1,000 (-10.0%)

12M Bull Case BreakoutTarget $1.89

$21,000

+$11,000 (+110.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCDA)

✓Walkthrough of BCDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.35%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.92H $0.92L $0.86C $0.90VOL 79.3K

RES: $1.49SUP: $0.86SMA50: $1.04SMA200: $1.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCDA Butterfly Map → + Track BCDA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCDA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCDA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCDA)

Health Care Rank #549 of 1016 ⚔️ ATYR vs BCDA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCDA vs. ATYR, ABOS, DYAI, PASG)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioCardia Inc. (BCDA) ranks #549 by composite RQD confidence (37/100, grade D-) and #864 by equity capitalization ($13.0M). Within this direct 5-issuer industry benchmark cohort, BCDA leads on earnings valuation at N/A trailing P/E, while BCDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BCDA at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCDA ACTIVE BioCardia Inc.	D-	37/100	—	—	-35.0%	+4.75%	$13.0M	Benchmark Subject
ATYR aTyr Pharma Inc.	D	46/100	—	—	-35.0%	+27.33%	$12.4M	/atyr-vs-bcda →
ABOS Acumen Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	+14.09%	$15.2M	/abos-vs-bcda →
DYAI Dyadic International Inc.	E	31/100	—	24.9%	-35.0%	-1.10%	$15.2M	/dyai-vs-bcda →
PASG Passage Bio Inc.	E	34/100	—	—	-35.0%	-3.77%	$11.1M	/pasg-vs-bcda →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000925741

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioCardia Inc. (BCDA) reported GAAP revenue of $23.2M (+3.5% vs. FY2024 revenue of $22.4M , and -28.9% cumulative change since FY2023) , GAAP net income of -$8.2M, operating cash flow of -$7.4M, and free cash flow of -$7.4M (+5.7% YoY). On the balance sheet, BCDA closed FY2025 with $3.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$23.2M	-$8.2M	-$7.4M	-$7.4M	$3.4M	—
FY2024 (FY)	2024-12-31	$22.4M	-$7.9M	-$7.9M	-$7.9M	$3.7M	—
FY2023 (FY)	2023-12-31	$32.6M	-$11.6M	-$10.0M	-$10.0M	—	—

3. BCDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BCDA compare to ATYR and ABOS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BCDA?

Where is BCDA trading relative to its 50-day, 200-day, and 52-week technical levels?

BCDA last traded at $0.90 (+4.75% on volume of 81,694 shares), positioning the stock -13.46% below its 50-day simple moving average ($1.04) and -15.89% below its 200-day simple moving average ($1.07). Across its 52-week range of $0.75 to $1.80, BCDA sits at the 14.3% percentile with a 14-day RSI of 40.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.01).

Direct Sub-Reports: BCDA RQD Cockpit BCDA 12M Forecast BCDA Earnings & Move BCDA Dividends & DRIP BCDA Insiders & 13F BCDA Whale Options BCDA Profit Sankey BCDA News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BCDA — BioCardia Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:51Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

BCDA scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

Fundamental Cash Engine (8 / 20): ROIC is -35% and FCF yield is 0%. For an investor, this indicates the business is not currently generating returns on invested capital or free cash, so any valuation rests on future outcomes rather than present earnings.
Whale 13F Flow (6 / 20): institutional accumulation and options positioning score weakly. Institutional support is a potential upside driver; its absence limits confidence in near-term demand for the shares.
Insider Conviction (5 / 20): SEC Form 4 and Congressional PTR cluster flow score weakly. Per the news wire, a single small CEO share purchase appears in the headlines, but the rating does not treat it as a cluster signal.
Macro Regime Fit (9 / 20): beta is 1.0 and sector sensitivity is scored as a moderate weakness. This means price movement is not dampened relative to the market.
Forensic Balance Sheet (10 / 20): Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings signal financial fragility and weak fundamental quality, which is a key valuation tradeoff: the low share price and small market capitalization reflect this risk profile.

Overall, for a prospective investor evaluating the stock today, the rating points to a high-risk, pre-profit profile where upside depends on catalysts (see news wire) rather than current cash generation.

2. Business Model, Unit Margins & SEC Financial Trajectory

BioCardia Inc. (BCDA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry.. Customers and product details are —

Operating and net losses persist across all three reported periods, and the market data shows a 0% gross, operating, and net margin with ROIC of -35%. The Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash was $2.5M in FY 2025 and $2.4M in FY 2024, against FCF outflows of -$7.4M and -$7.9M, respectively. Balance sheet posture is therefore thin relative to annual cash burn, with debt reported as N/A.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: FDA acceptance of the Helix Catheter pre-submission and a reported FDA view that the heart-failure trial may support approval could be catalysts for the shares. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 5/20, sustained execution supports upside toward the top of the $0.75 – $1.80 52-week range.
🐻 Primary Bear Case: The company reports $0.0M revenue, -35% ROIC, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9, with cash of $2.5M against FY 2025 free cash outflows of -$7.4M. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — Sector correlation data is — The main 2nd-order watch item an investor should track is the regulatory path: per the news wire, the FDA acceptance and procedural steps are the primary ripple channel, since clearance or delay would affect the company directly without any identified supply-chain transmission.

Key Question #1: What is the current cash runway against the reported annual free cash outflows of -$7.4M (FY 2025)?
Key Question #2: What is the status and timing of the Helix Catheter marketing clearance process referenced in the news wire?
Key Question #3: Is any debt outstanding, given debt is reported as N/A across all periods?

BCDA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioCardia Inc. (BCDA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BCDA Debate Forum (3) ↓

🟡 MARKET WIRE Investing.com • 20h ago

BioCardia president and CEO Peter Altman buys $475 in BCDA shares

Investing.com report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment.

Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

BioCardia (NASDAQ:BCDA) Penny Stock Up 6% Pre-Market on an FDA Procedural Step

kalkine.ca report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Quiver Quantitative • 1d ago

BioCardia Announces FDA Acceptance of Helix Catheter De Novo Pre-Submission for Marketing Clearance

Quiver Quantitative report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

At $0.95 per share, BioCardia (BCDA) CEO buys 500 shares across two purchases.

Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A device for heart treatments has data from 15 trials and nearly 500 patients. FDA accepted its package.

Stock Titan report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investing.com India • 1d ago

FDA accepts BioCardia pre-submission for Helix catheter By Investing.com

Investing.com India report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Kalkine Media • 1d ago

FDA Accepts BioCardia's De Novo Pre-Submission for Helix Catheter, Review Scheduled This Quarter

Kalkine Media report covering BioCardia Inc. (BCDA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BCDA Bull vs. Bear Conversation Board — What's Your Call at $0.90?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCDA 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.10 (+27.9%)

📌 Pinned Debate

FDA acceptance of the Helix Catheter pre-submission and a reported FDA view that the heart-failure trial may support approval could be

Picked up a starter position in BCDA in my $100K Virtual Cash book at $0.86. FDA acceptance of the Helix Catheter pre-submission and a reported FDA view that the heart-failure trial may support approval could be catalysts for the shares.. Trading inside a $0.75–$1.80 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $0.86 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.72 (-16.3%)

Spot @ $0.86

The company reports $0.0M revenue, -35% ROIC, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9, with cash of $2.5M against FY 2

Careful chasing BCDA at $0.86. The company reports $0.0M revenue, -35% ROIC, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9, with cash of $2.5M against FY 2025 free cash outflows of -$7.4M.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.72 on multiple compression.